CoChat

Sifting through a failed Alzheimer trial: What biomarkers tell us about what happened

Knopman, David S. · 2018 · Neurology

The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.

Abstract

The pathogenesis of Alzheimer disease (AD) remains a work in progress even as we approach the 50-year anniversary of the modern exploration of late-life dementia. The β-amyloid (Aβ) peptide has been a target of repeated therapeutic efforts for the last 2 decades. It seems like an obvious target: people dying with dementia often have high burdens of Aβ in one form or another throughout their brains. Over the last decade, several large clinical trials attempted to lower brain Aβ levels. One of them, with the anti-amyloid monoclonal antibody bapineuzumab, serves as the basis of a report in this issue of Neurology® .1

Overview

Integrity signals

Registry

Crossref · 10.1212/wnl.0000000000005073

Cites

10 of 10 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 10 references

Cited by

See all 6

Metadata

Authors
Knopman, D. S.
Affiliations
Mayo Clinic (US)
Corresponding author
Knopman, David S.
Venue
Neurology
Published
2018-03-06
Volume
90
Issue
10
Pages
447-448
ISSN
  • 0028-3878 (ISSN-L)
  • 1526-632X
OpenAlex
W2786312344
Cited by
5
References
10
Citations by year
2022: 3 · 2020: 2
Type
journal article
Language
en
Open access
closed
Locations
  • Neurology (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • Biogen
  • Mayo Foundation for Medical Education and Research
  • H. Lundbeck A/S
  • National Institutes of Health
Topics
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
Keywords
Alzheimer's disease, bapineuzumab, anti-amyloid monoclonal antibodies, amyloid-beta, anti-amyloid therapy, clinical trial failure, late-onset dementia, Alzheimer disease pathogenesis
MeSH terms
Alzheimer Disease, Humans, Biomarkers, Randomized Controlled Trials as Topic, Antibodies, Monoclonal, Humanized

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Sifting through a failed Alzheimer trial: What biomarkers tell us about what happened. https://app.cochat.ai/papers/10.1212/wnl.0000000000005073
The paper
Knopman, D. S. (2018). Sifting through a failed Alzheimer trial: What biomarkers tell us about what happened. Neurology. https://doi.org/10.1212/wnl.0000000000005073

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.